(Reuters) - The company is targeting savings in its pharmaceuticals division, where it will consolidate certain operations. The company noted that it faces major patent expirations over the next few years to several drugs.
The maker of consumer health products, pharmaceuticals and medical devices is also primarily seeking savings from its Cordis franchise, which competes in the market for drug-coated stents. Such stents have been hit with safety concerns after being initially hailed as revolutionary.
Read more at Reuters.com Business News
The maker of consumer health products, pharmaceuticals and medical devices is also primarily seeking savings from its Cordis franchise, which competes in the market for drug-coated stents. Such stents have been hit with safety concerns after being initially hailed as revolutionary.
Read more at Reuters.com Business News
No comments:
Post a Comment